MedTrace Logo

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

NCT02728830 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-02-21

Study results available
· View outcomes & findings →

Summary

The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.

Conditions

  • Gynecologic Neoplasms
  • Epithelial Ovarian Cancer
  • Uterine Endometrial Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg IV

Sponsors & Collaborators

Principal Investigators

  • Angeles A Secord, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-01-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728830 on ClinicalTrials.gov